COMMUNIQUÉS West-GlobeNewswire

Iridex Announces Plans to Relocate Headquarters
02/02/2026
Move expected to generate significant cost savings MOUNTAIN VIEW, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader providing innovative and versatile laser-based medical [...]
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
02/02/2026
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, [...]
Palvella Therapeutics Announces Scientific Publication in Clinical and Experimental Dermatology Highlighting a Systematic Review of Real-World Statin Evidence and Persistent Treatment Gaps Resulting from the Lack of FDA-Approved Therapies in Porokeratosis
02/02/2026
Publication includes a systematic review of 24 studies describing off-label cutaneous application of statins in porokeratosis Preliminary case reports suggesting clinical benefit underscore unmet need for development of [...]
EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to <30 kg
02/02/2026
EURneffy 1 mg will be the first and only needle-free adrenaline available to younger children in the European Union ARS Pharma’s partner, ALK-Abelló A/S, who owns the rights to market EURneffy in the EU, will distribute [...]
Ringing in Your Ears? ASHA Shares Facts About a Common Yet Misunderstood Health Issue
02/02/2026
Association Stresses Importance of Prevention and Availability of Treatment for Tinnitus Awareness Week Rockville, Md., Feb. 02, 2026 (GLOBE NEWSWIRE) -- As many as one in three people globally have experienced tinnitus [...]
Targeted Genomics Launches Celiac Genetic Testing Services for Texas Physicians
02/02/2026
Partnering with Texas pathology group enables a genetics-focused strategy to address the hidden epidemic of celiac disease IRVINE, Calif. and SAN ANTONIO, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Targeted Genomics LLC , [...]
Wave Life Sciences Announces Plans to Accelerate Regulatory Engagement with Full Control of WVE-006 for Alpha-1 Antitrypsin Deficiency
02/02/2026
WVE-006 is a first-in-class RNA editing therapeutic candidate designed to correct the root cause of disease for the 200,000 individuals in the U.S. and Europe living with AATD; no currently approved therapies address [...]
Standard Dental Labs Announces Acquisition of BRLIT Dental Laboratory, Inc.
02/02/2026
ORLANDO, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (“SDL”), a Florida-based dental laboratory platform focused on high-quality clinical outcomes and long-term practitioner relationships, today [...]
MAPS and Columbia University Partner on First-of-its-Kind Study of MDMA-Assisted Couples Therapy
02/02/2026
Anonymous survey with optional confidential interviews will document how practitioners facilitate MDMA-assisted couples therapy Findings to inform ethical guidelines, future clinical trial protocols, and policy [...]
60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership
02/02/2026
GoodRx to offer prescription savings of up to 30% for ARAKODA ® ( tafenoquine ) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategy Partnership will improve [...]
MoonLake Announces FDA Fast Track Designation for Sonelokimab Palmoplantar Pustulosis (PPP) and Provides Details on Upcoming Investor Day
02/02/2026
The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positive results from the [...]
vTv Therapeutics Amends License Agreement with Newsoara Biopharma Co. Ltd. for PDE4 inhibitor, HPP737
02/02/2026
Strategic amendment transforms regional partnership into global collaboration; Newsoara gains exclusive worldwide license to develop and commercialize novel PDE4 inhibitor vTv to receive $20 million upfront payment [...]
Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate
02/02/2026
Product is currently under review with the FDA Potential approval and launch mid-2026 DEER PARK, Ill., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative [...]
BrainCo’s Brain-Computer Interface Headband Supporting Social Skills Development in Children with Autism
02/02/2026
Somerville, MA, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Improving social communication skills in children with autism has traditionally relied on structured teaching approaches and stable support environments. With the [...]
Press Release: Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease
02/02/2026
Sanofi’s venglustat met all primary endpoints in a phase 3 study of type 3 Gaucher disease In the LEAP2MONO phase 3 study, venglustat, dosed orally once daily, demonstrated clinically meaningful efficacy in patients [...]
Communiqué de presse : Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3
02/02/2026
Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3 Dans l’étude de phase 3 LEAP2MONO, le venglustat, administré par voie orale une [...]
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
02/02/2026
REYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today [...]
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
02/02/2026
REYKJAVIK, ICELAND (February 2, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has [...]
CROSSJECT annonce l’initiation de couverture de son titre par Portzamparc (Groupe BNP Paribas)
02/02/2026
CROSSJECT annonce l’initiation de couverture de son titre par Portzamparc (Groupe BNP Paribas) DIJON, France - 02 février 2026 (07h15CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), la société pharmaceutique de [...]

Pages